BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Anbenitamab repodatecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Anbenitamab repodatecan\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06751485-9179@assetmemo.bio
DTSTAMP:20261121T004107Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Anbenitamab repodatecan: Phase 3 readout est. (NCT06751485)
DESCRIPTION:Anbenitamab repodatecan\, phase 3.\nStudy: JSKN003 in Platinum-
 Resistant\, Relapsed Epithelial Ovarian Cancer\nEstimated primary completi
 on: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /anbenitamab-repodatecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06751485
URL:https://assetmemo.bio/drug/anbenitamab-repodatecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07545044-9179@assetmemo.bio
DTSTAMP:20261121T004107Z
DTSTART;VALUE=DATE:20270529
DTEND;VALUE=DATE:20270530
SUMMARY:Anbenitamab repodatecan: Phase 2 readout est. (NCT07545044)
DESCRIPTION:Anbenitamab repodatecan\, phase 2.\nStudy: A Study of JSKN003 V
 ersus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Li
 ne Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer\nEsti
 mated primary completion: 29 May 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/anbenitamab-repodatecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07545044
URL:https://assetmemo.bio/drug/anbenitamab-repodatecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07384377-9179@assetmemo.bio
DTSTAMP:20261121T004107Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Anbenitamab repodatecan: Phase 3 readout est. (NCT07384377)
DESCRIPTION:Anbenitamab repodatecan\, phase 3\, Colorectal Cancer.\nStudy: 
 JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive 
 and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin\, 
 5-Fu\, and Irinotecan\nEstimated primary completion: 30 November 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/anbenitamab-repodatecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0738
 4377
URL:https://assetmemo.bio/drug/anbenitamab-repodatecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-9179@assetmemo.bio
DTSTAMP:20261121T004107Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Anbenitamab repodatecan: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Anbenitamab repodatecan\, phase 2\, HER2-Positive Breast Cancer
 .\nStudy: Fudan University Shanghai Cancer Center Breast Cancer Precision 
 Platform Series Study- Neoadjuvant Therapy\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/anb
 enitamab-repodatecan#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/anbenitamab-repodatecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998771-9179@assetmemo.bio
DTSTAMP:20261121T004107Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Anbenitamab repodatecan: Phase 2 readout est. (NCT06998771)
DESCRIPTION:Anbenitamab repodatecan\, phase 2.\nStudy: JSKN003 Combined Tre
 atment of HER2-positive Gastric Cancer\nEstimated primary completion: 30 J
 une 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/anbenitamab
 -repodatecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06998771
URL:https://assetmemo.bio/drug/anbenitamab-repodatecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
